
Fraud Prevention and the Ministry of Health are warning of the risks of unwanted pregnancies and sexually transmitted infections.
Fraud Prevention and the Ministry of Health are warning of around thirty references to non-compliant condoms sold online and in pharmacies, presenting risks of STIs and unwanted pregnancies.
AI-generated summary
The online sale of non-compliant medical devices poses major health risks.
Around thirty references of non-compliant condoms, sold online and in pharmacies in recent months, are likely to lead to unwanted pregnancies or sexually transmitted infections, alert the Fraud Repression and the Ministry of Health this Friday, August 21. Around a thousand boxes, or “more than 40,000 non-compliant condoms”, were sold on the internet, “mostly” via “Asian” distributors, their press release specifies.
According to the Rappel Conso website, the brands concerned are: Friday Bae (The Condom), Okamoto (003 and 002), Sagami (Sagami Original 002, sold on Amazon), and My Lubie, whose products are sold on Amazon, in pharmacies and by various brands: Nuoo, Mademoiselle Bio, Monoprix, Ayanature, Passage du Désir.
The products identified do not have a CE marking or any European conformity assessment and “for the most part, packaging in French”, specify the DGCCRF and the Directorate General of Health (DGS). But checks in stores and pharmacies also made it possible to identify "two references" of condoms having obtained the CE marking and yet non-compliant due to a "risk of bursting" for one and "the presence of perforations" for the other: some "260,000 units" were also the subject of "recalls launched at the end of May and the beginning of August", adds the press release.
Online platforms were ordered to “immediately remove the advertisements” for the products concerned – 36 were immediately removed – and to inform “third-party sellers”. Several “have” committed to examining their verification systems and filtering rules “on these products,” the press release specifies.
The stakes are high: non-compliant condoms can “present serious risks to the health and safety of users: sexually transmitted infections, unwanted pregnancies”, remind the authorities. They recommend that consumers who have used these condoms be screened for sexually transmitted infections and take a pregnancy test if a late period is noted.
The European conformity marking (CE marking) is “guarantor of the essential safety requirements” with which manufacturers must comply: consumers must check its presence, reminds the DGCCRF, like that of a user manual in French, and ensure the condition of the packaging and the expiration date of the products. It is not infallible - here, certain CE marked products were not compliant - but it already limits the risk.
AI outlook — possibilities, not facts
Pregnancy screening and tests recommended for users
Very likely · Within days

La DGCCRF a alerté sur le rappel d'environ 40 000 préservatifs défectueux vendus en ligne et en pharmacie. Ces produits présentent des risques de rupture ou de perforations, pouvant entraîner des grossesses non désirées ou des infections sexuellement transmissibles.
Les vagues de chaleur en Europe ont causé plus de 30.000 décès excédentaires depuis fin mai, selon EuroMomo. L'Allemagne, la France et l'Espagne enregistrent les bilans les plus lourds, touchant particulièrement les personnes âgées de 75 ans et plus.
La DGCCRF et le ministère de la Santé alertent sur la vente de 40.000 préservatifs non conformes en France. Sans marquage CE ou présentant des risques de perforation, ils font courir des risques d'IST et de grossesses non désirées.

L'Assurance-maladie a mis à jour sa documentation sur l'encéphalomyélite myalgique, reconnaissant cette pathologie comme une maladie physique invalidante et non psychologique, une avancée saluée par les associations de patients.
Face aux critiques, le gouvernement français renonce au doublement immédiat du plafond annuel des franchises médicales et opte pour une indexation sur l'inflation depuis 2005, selon la ministre de la Santé Stéphanie Rist.

Moderna et Merck ont testé avec succès une thérapie combinant immunothérapie et vaccin personnalisé contre les rechutes de mélanome, réduisant significativement le risque de récidive chez plus de 1100 patients suivis.